1. Home
  2. VRAX vs ENSC Comparison

VRAX vs ENSC Comparison

Compare VRAX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • ENSC
  • Stock Information
  • Founded
  • VRAX 2013
  • ENSC 2003
  • Country
  • VRAX United Kingdom
  • ENSC United States
  • Employees
  • VRAX N/A
  • ENSC N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • ENSC Health Care
  • Exchange
  • VRAX Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • VRAX 7.3M
  • ENSC 7.9M
  • IPO Year
  • VRAX 2022
  • ENSC N/A
  • Fundamental
  • Price
  • VRAX $1.87
  • ENSC $5.40
  • Analyst Decision
  • VRAX
  • ENSC
  • Analyst Count
  • VRAX 0
  • ENSC 0
  • Target Price
  • VRAX N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • VRAX 304.3K
  • ENSC 26.4K
  • Earning Date
  • VRAX 02-05-2025
  • ENSC 03-14-2025
  • Dividend Yield
  • VRAX N/A
  • ENSC N/A
  • EPS Growth
  • VRAX N/A
  • ENSC N/A
  • EPS
  • VRAX N/A
  • ENSC N/A
  • Revenue
  • VRAX $84,872.00
  • ENSC $4,421,404.00
  • Revenue This Year
  • VRAX $5,169.18
  • ENSC $89.78
  • Revenue Next Year
  • VRAX $66.97
  • ENSC N/A
  • P/E Ratio
  • VRAX N/A
  • ENSC N/A
  • Revenue Growth
  • VRAX 7.03
  • ENSC 40.41
  • 52 Week Low
  • VRAX $0.60
  • ENSC $2.12
  • 52 Week High
  • VRAX $9.00
  • ENSC $14.67
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 48.66
  • ENSC 35.78
  • Support Level
  • VRAX $1.65
  • ENSC $5.34
  • Resistance Level
  • VRAX $2.10
  • ENSC $6.14
  • Average True Range (ATR)
  • VRAX 0.22
  • ENSC 0.43
  • MACD
  • VRAX 0.01
  • ENSC -0.04
  • Stochastic Oscillator
  • VRAX 42.47
  • ENSC 9.49

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: